Vertex Pharmaceuticals Acquires Crinetics for $10 Billion to Expand Rare-Disease Portfolio
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a deal valued at approximately $10 billion. The acquisition aims to expand Vertex's rare-disease business, with access to approved and experimental therapies such as Palsonify and Atumelnant. The transaction is expected to close by the third quarter of 2026.
Topics: M&A pharmaceuticals rare-disease-treatment